Gilead Sciences, Inc. (GILD)

Several events have influenced Gilead Sciences' stock price over the past six months. In Q1 2025, the company missed revenue expectations but surpassed adjusted EPS estimates. In Q2 2025, Gilead's shares rose following results that beat both adjusted EPS and revenue forecasts. The U.S. patent exclusivity for Biktarvy was extended until 2036. An experimental HIV treatment was terminated in early testing. Gilead presented new findings from its antiviral research and development programs at IDWeek 2025. Late-breaking data from the Phase 3 ASCENT-03 study for Trodelvy were presented at ESMO 2025 Congress. The launch of Yeztugo has shown promising early physician feedback.

The demand for Gilead Sciences' products exhibits varying degrees of seasonality depending on the therapeutic area. Demand for influenza antivirals is seasonal and can be unpredictable, while demand for antiviral drugs for chronic viral infections like HIV and hepatitis is primarily driven by the rising global prevalence of these infections and increasing access to healthcare. Demand for oncology drugs is generally not characterized by seasonality.

Gilead Sciences, Inc. is an American biopharmaceutical company focused on researching, developing, and commercializing medicines for life-threatening diseases, operating within the Health Technology sector, specifically in the Biotechnology and Pharmaceutics industries. Initially focused on antiviral drugs for HIV/AIDS, hepatitis B, hepatitis C, and influenza, Gilead has diversified to include treatments for liver diseases, hematology, oncology, and inflammation and respiratory diseases. Major products include treatments and preventions for HIV/AIDS, liver diseases, oncology, influenza and COVID-19, and other notable products.

Gilead Sciences maintains a global presence, with its headquarters in Foster City, California, United States. The company operates in North America, Europe, and Australia, and its medicines are available in more than 35 countries worldwide.

In the past year, Gilead Sciences has maintained a positive brand reputation, particularly as an employer, being recognized on Forbes' lists for "America's Best Employers For Company Culture (2025)" and "America's Best Employers for Women (2025)." Gilead and its subsidiary Kite Pharma have reinforced their commitment to transforming cancer care, as highlighted by new data presented at the ESMO 2025 Congress.

Gilead Sciences, Inc. has a significant portion of its shares owned by institutional investors, accounting for 83.67%, while insider shareholders hold a smaller percentage, at 0.27%.